Selecta Biosciences raises $20 million
Selecta Biosciences said Wednesday it has secured $20 million in equity funding from new and all of Selecta’s existing investors. Including the $20 million, Selecta said it has obtained a total of $78.6 Million in funding to date. Investors include Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments. Selecta is a clinical stage biotechnology company that is developing a class of targeted antigen-specific immune therapies.
15 October 2014•3 mins read
